API
< Back to all clusters
[HEALTH] · Italy, Spain, Germany, Romania, Czechia · 36 sources

started · updated

European Commission authorizes daraxonrasib for metastatic pancreatic cancer

The European Commission has authorized the sale of daraxonrasib, marketed under the name Rasonque, for the treatment of adults with metastatic pancreatic adenocarcinoma who have already received at least one systemic therapy. The decision follows an accelerated assessment by the European Medicines Agency (EMA).

Clinical data from the phase 3 RASolute 302 study indicates that the drug, which is administered as a once-daily oral tablet, significantly extends survival. Patients treated with daraxonrasib showed a median survival of approximately 12.4 to 13.2 months, compared to 6.7 months for those receiving standard chemotherapy. The treatment also doubled the median time without disease progression from 3.6 to 7.2 months.

While the authorization allows for commercialization across the European Union and the European Economic Area, individual member states must still determine pricing and reimbursement protocols. In Italy, the Italian Medicines Agency (AIFA) has initiated a rolling review to facilitate rapid access. In Spain, patient associations are calling for expedited national funding to ensure equitable access to the new therapy.

Entities

AIFA · Aiom · Castellana Grotte · European Commission · European Medicines Agency · Humanitas · IRCCS Saverio De Bellis · Italian Medicines Agency · Italy · Rasonque · Revolution Medicines · SUD4PANCREAS ODV-ETS

Claims

What the coverage asserts, and how many sources carry each claim.

Sources